Current Report Filing (8-k)
December 15 2017 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 15, 2017
Applied DNA
Sciences, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
(State or other jurisdiction
of incorporation)
|
001-36745
(Commission File Number)
|
59-2262718
(IRS Employer
Identification No.)
|
50 Health Sciences Drive
Stony Brook, New York 11790
(Address of principal executive offices; zip
code)
Registrant’s telephone number, including
area code:
631-240-8800
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
¨
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02 Results of Operations and Financial Condition.
On December 15, 2017, Applied DNA Sciences, Inc. (“Applied
DNA Sciences” or the “Company”) issued a press release announcing its selected preliminary unaudited results
of operations for the fiscal year and quarter ended September 30, 2017. A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
Item 8.01 Other Events.
The information provided in response to Item 2.02 of this Current
Report is incorporated by reference into this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
(
d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: December 15, 2017
|
APPLIED DNA SCIENCES, INC.
|
|
|
|
|
By:
|
/s/ James A. Hayward
|
|
Name:
|
James A. Hayward
|
|
Title:
|
Chief Executive Officer
|
EXHIBIT INDEX
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024